Certara, Inc. (CERT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

Director election results show strong shareholder support for Arjun Bedi and Jon Resnick with over 99% approval, while Stephen McLean received notably lower support at 81.4% approval, suggesting potential governance or performance concerns with this director.
RSM US LLP was overwhelmingly ratified as the independent auditor with 99.5% approval and zero broker non-votes, indicating strong confidence in the company's financial reporting and audit processes.
Executive compensation was approved with 98.1% shareholder support, demonstrating investor confidence in management's pay practices and overall leadership performance despite Stephen McLean's lower director approval rating.
Broker non-votes of approximately 19.9 million shares on director elections suggest institutional investors may be abstaining or facing voting restrictions, representing roughly 7.6% of total votes cast on that proposal.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-11

Certara completed the divestiture of its medical writing and regulatory services business to Veristat for $85 million in cash on May 8, 2026, representing a strategic shift toward core competencies and potential cash generation for debt reduction or reinvestment.
The transaction structure includes $15 million in escrow (subject to post-closing covenants) and up to $35 million in contingent earn-out payments based on business performance, indicating seller confidence but also retention of downside risk exposure.
The sale proceeds provide immediate liquidity that could improve Certara's financial position, though the divestiture reduces revenue-generating assets and suggests management prioritization of margin expansion or return of capital over growth in that segment.

Filed: 2026-04-22

Certara is divesting its global medical writing and regulatory services business to Veristat for $100 million upfront cash plus up to $35 million in contingent earn-out payments, representing a strategic portfolio optimization to focus on core operations.
The transaction structure includes $15 million held in escrow pending satisfaction of closing conditions, providing some downside protection while the earn-out component ties future value realization to post-closing business performance over a specified period.
The deal is subject to customary closing conditions including material adverse effect clauses and completion of internal reorganization steps, with transition services to be provided post-closing, indicating an orderly separation process.

Other reports for Certara, Inc.

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.